Purpose. To explore the expression of the TRAV gene in peripheral blood mononuclear cells (PBMCs) and in tumor-infiltrating lymphocytes (TILs) in the patients with breast cancer using a DNA melting curve (FQ-PCR) technique for T cell receptor (TCR) alpha chain CDR3 spectratyping.
Most human mature T cells express alpha or beta T cell receptors (TCRs) for specific recognition of antigenic peptides in the context of major histocompatibility complex (MHC) molecules. Three hypervariable or complementaritydetermining regions (CDR1, CDR2, and CDR3) of the TCR have been identified in the alpha and beta chains [1] . The TCR alpha chain gene is rearranged by TRAV, TRAJ, and TRAC gene segments. The region of the TRAV/TRAJ junction corresponds to the TCR alpha chain CDR3. Different sizes or sequences of CDR3 (TCR alpha CDR3 or TCR beta CDR3) correspond to different T cell clones. Therefore, the analysis of the variable region of the TCR CDR3 gene can be used to determine the clonal features of a particular T cell response [2, 3] .
TCR beta chain and the TCR alpha chain CDR3 spectratyping are of three main types. TCR CDR3 shows preferential usage TRBV or TRAV; There are common motifs in the CDR3 region or same CDR3 sequences [3, 4] . A correlation between TCR beta chain CDR3 spectratyping and tumor characteristics have been reported for lung cancer [5, 6] , gastric cancer [7] , colorectal cancer [8, 9] , melanoma [10] , glioma [11] , and uterine, and ovarian cancers [12] . There appears to be less correlation between TCR alpha-chain CDR3 spectratyping and tumor characteristics [3, 13, 14 ] .
In the research of TCR bias and breast cancer, Kirii et al. found that TCR V beta 9 (TRBV9), V beta13.1 (TRBV13.1), and Vbeta17 (TRBV17) were predominantly expressed on specific cytotoxic T cells in the pancreas of breast tumor patients. No preferential expression was found in the TCR V alpha repertoire [15] . Ito et al. reported that there was a predominant TCR V beta 18 family (TRBV18) of T cell clonal expansion in the CD8 + T cell subset in the breast cancer patients' lymph nodes, but in most breast cancer patients, peripheral blood mononuclear cells and lymph nodes dominantly express CD8 + T cell clones of the TCR V beta gene families (TRBV) [16] . In this study, we observed preferential usage of certain TRAV genes in the peripheral blood monocytes (PBMCs) and tumor-infiltrating lymphocytes (TILs) of patients with breast cancer.
Patients and methods
Patients. Peripheral blood samples and tissue samples were collected with informed consent from thirty patients with breast cancer. Peripheral blood was drawn prior to surgical procedures. Tissue samples were obtained from surgical dissections. All the patients were negative for HbsAg, seronegative for markers of hepatitis A, C, D, and E viruses and HIV, and none had clinical or laboratory evidence of other infectious diseases, types of tumors, or immunological disorders. The study protocol was approved by the local ethics committee. Clinical data are summarized in Table 1 .
Primers. The primers for TRAV family-specific amplification were previously described [17, 18] . There were 34 TRAV sense primers and a common antisense primer to TRAC. Amplification of GAPDH (sense: 5'-aggggtctacatggcaact-3'; antisense: 5'-cgaccactttgtcaagctca-3') was used as a control. All the primers were synthesized by the Shang-Hai Invitrogen Corporation of China.
Isolation of mononuclear cells. Five milliliters of peripheral blood were taken from each patient. PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation. Breast cancer tissue was collected and digested by trypase.
Extraction of RNA and synthesis of the first-strand cDNA. Total RNA was extracted from PBMCs and TILs using the Omega RNA extraction kit according to the manufacturer's instructions. Total RNA was reversely transcribed mixed with 250 pm oligo(dT), 200 U Moloney murine leukemia virus (M-MuLV) reverse transcriptase, and 2 μl of 10 mM dNTP mix (MBI-Fermentas, cDNA synthesis kit) in a total volume of 20 μl (six reactions for every sample). The cDNA was stored at -80 °C before use as a template for PCR amplification.
FQ-PCR amplification of CDR3 cDNA and CDR3 spectratyping. FQ-PCR was carried out in a 20 μl volume with 10 μl 2× Real-time PCR Master Mix (TOYOBO), which contained Taq polymerase, dNTPs, PCR buffers, and SYBR green I. The final concentration of each primer was 0.3 μM, and 1 μl cDNA was added to the reaction mixture as the PCR template. Reactions were performed in a DNA Engine Opticon® 2 System and analyzed with Opticon Monitor 3.0 software (Bio-Rad) using the following procedure: incubation at 94 °C for 3 min, 94 °C melting for 20 sec, primer annealing at 56 °C for 30 sec, and extension at 72 °C for 30 sec for 40 cycles. To ensure an accurate fluorescence signal of the desired amplification products, a high-temperature fluorescence measurement was performed in the fourth step of the PCR run. The fluorescence signal was acquired every cycle at 80 °C for 2 sec. After extension at 72°C for 10 min, a melting step was performed by slow heating from 75 °C to 95 °C with a ramping of 0.2 °C/sec, during which the fluorescence signal was measured continuously. Amplification reactions for each sample were carried out using the GAPDH specific primer paired with every specific primer for each TRAV gene family and melting temperatures (Tms) were determined [9, 19, 20, 21] .
Sequencing of CDR3 region. We selected the PCR products of TRAV families showing predominant usage, amplified in conditions used for common PCR, and sequenced them on an ABI 377 DNA sequencer (SinoGenoMax Co, Ltd.). DNA tools version 6 was used for analysis [9, 21] .
Results
TCR alpha CDR3 spectratyping showed preferential expression of certain TRAV genes in the PBMCs and TILs of all 30 patients with breast cancer. The most common TRAV genes expressed in PBMCs from these patients (exceeding frequencies of 30%) were TRAV1.1, TRAV9, and TRAV29. In TILs, two genes were expressed by more than 30% of patients: Table 2 . There were no significant correlations between TRAV gene preferential usage in TILs and expression of tumor markers including estrogen receptor (ER), progesterone receptor (PR), pS2, C-erbB-2, nm23, P53, and Ki-67. However, some of the TRAV gene preferential usage frequency exceeded 20% in patients who expressed certain tumor markers. For example, five of eight patients who had high levels of expression of ER highly expressed TRAV 32 and TRAV 1.1 (Table 3) .
We observed some common motifs in the amino acid sequences of the TCR CDR3 region (Table 4) AV1.1(4/9); AV22(4/9); AV10(3/9); AV12(3/9); AV3(2/9); AV8(2/9); AV29(2/9);AV1.2; AV4.2; AV6; AV15; AV17; AV23; AV25; AV31;AV32 AV1.1(4/9); AV22(4/9); AV10(3/9); AV12(3/9); AV3(2/9); AV8(2/9); AV29(2/9) ≤5% P2 P6 P7 P8 P9 P14 P20 P25 P30
AV1.1(6/9); AV12(3/9); AV29(3/9); AV22(2/9); AV32(2/9); AV1.2; AV3; AV4.1; AV8; AV14;AV15; AV16; AV17; AV18; AV19; AV23;AV25 AV1.1(6/9); AV12(3/9); AV29(3/9); AV22(2/9);AV32(2/9)
Discussion
The CDR3 region of the TCR varies among T cell populations. Specific recognition of a peptide on a certain T cell can induce clonal expansion of T cells that express a particular TCR V gene product. The development of the TCR V gene preferential usage is a sign of an antigen-driven immune response [3, 4, 22] . Analysis of the CDR3 size and distribution pattern (spectratyping) can be used to define the degree of clonality of the T cells and has been widely exploited in the research of T cell anti-tumor response.
In this study, we used the FQ-PCR technique to determine TRAV gene expression in PBMCs and TILs from patients with breast cancer. We found that one or more TRAV families were preferentially expressed in each patient; each of the patients exhibited different TRAV profiles (Table 2) . In individual patients, TRAV gene preference generally differed in PBMCs and TILs. Koichi et al. reported that PBMCs and lymph nodes of most breast cancers patients expressed a dominant CD8 + T cell clone although the number of dominant clones was higher in PBMCs than in the lymph nodes. We did not find the significant different number of the TRAV gene preferential usage between the PBMCs (totals of 119 TRAV gene preferential usage) and TILs (totals of 110 TRAV gene preferential usage) in thirty patients with breast cancer (Table 2) [16] . In the PBMCs of the 30 breast cancer patients we tested, the most commonly expressed TRAV genes were TRAV1.1, TRAV9, and TRAV29. In TILs, TRAV1.1 and TRAV22 were detected most frequently (Fig. 1) . Furthermore, 77% (23/30) of the breast cancer patients had the same TRAV gene preferential usage in PBMCs and TILs, and the most highly expressed was TRAV1.1 (Table 2) . Although we did not find a significant correlation 
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Relative number PBMC TIL Fig. 1 The frequency of the preferential usage of TRAV CDR3 families in 30 patients with breast cancer � between TRAV gene usage and tumor marker expression, certain frequencies exceeded 20% (Table 3 ). All the common TRAV gene preferential usage maybe related to the presence of a certain associated tumor antigen (TAA). Robbins et al. reported that tumor cell antigens in tumor tissue in situ or transferred to the blood circulation are likely to activate the body's immune system [23] . Zhang et al. also reported that T cell clonal proliferation is detected in patients with rectal cancer; these patients had anti-tumor T lymphocytes [24] . Moreover, in some patients with tumors, monoclonal proliferative T lymphocytes activated by tumor antigen are transferred into PBMCs [25] . Other studies reported that minimal residual disease and tumor metastasis results in tumor-associated antigens in the blood circulation and continuously stimulated peripheral blood T lymphocytes. Under certain conditions, clonal proliferation in tumor tissue results in T lymphocytes in the blood. Unconformity with solid tumors may be related to tumor type, level of metastasis, and detection methods [26] . Determination of whether breast cancer-associated antigen is correlated with a high frequency of usage of certain TRAV genes will require analysis of larger numbers of patients with more advanced molecular biology techniques than available for this study.
We found that the amino acid sequence of the TCR CDR3 regions in the samples evaluated in our study showed some common motifs (Table 4 ). Several reports indicate that the CDR3 sequence of antigen-specific T cells that recognize the same peptide have identical CDR3 amino acid motifs [3, 27, 28] . Whether the motifs we identified are breast cancer-specific must be further affirmed. This type of analysis of gene expression in patient serum and tumor tissue may provide guidance for individualized T cell-directed therapy for breast cancer.
